top of page

PRODUCTS
- CANCER PRE-SCREENING
- BRCA GERMLINE
TECH & SCIENCE
CLINICAL TRIALS
- THE RAINBOW STUDY
- THE PINK STUDY
ABOUT
LET'S CONNECT
INVEST

ABOUT / NEWS & MEDIA

News & Media

Latest CEO Interviews

DISCLAIMER

The securities referred to in this website may be sold only to accredited investors, which for natural persons, are investors who meet certain minimum annual income or net worth thresholds. These securities are being offered in reliance on an exemption from the registration requirements of the Securities Act and are not required to comply with specific disclosure requirements that apply to registration under the Securities Act. The Securities and Exchange Commission has not passed on the
merits of or given its approval to the securities, the terms of the offering, or the accuracy or completeness of any offering materials. The securities are subject to legal restrictions on transfer and resale and investors should not assume that they will be able to resell their securities. Investing in securities involves risk, and investors should be able to bear the loss of their investment. The securities referred to in this website are being offered only by means of the Company’s Private Offering Memorandum

SAFE HARBOR STATEMENT

Matters discussed in this website contain forward-looking statements. When used in this update, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with our history of losses and our need to raise additional financing, the acceptance of our products and technology in the marketplace, our ability to demonstrate the commercial viability of our products and technology and our need to increase the size of our organization. Further information on the Company's risk factors is contained in the Company's Private Offering Memorandum. The Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason except as may be required under applicable law.

BIO-AI HYBRID PLATFORM
THE CANINE ADVANTAGE
BREATH SCIENCE
CANCER PRE-SCREENING
BRCA GERMLINE
THE RAINBOW STUDY
CANINE WELFARE
OUR STORY
TEAM & INVESTORS
LET'S CONNECT

ALL RIGHTS RESERVED,
SPOTITEARLY 2025

TERMS & CONDITIONS

CLIA registration: 99D2307137

USPTO patent pending: WO2023239834A1

hello@SpotitEarly.com

ALL RIGHTS RESERVED,
SPOTITEARLY 2025

SpotitEarly tests are not intended to replace current screening procedures, but rather to be used as an additional pre-screening layer to complement preventative protocols already in place.

The SpotitEarly tests have not been approved by the Food and Drug Administration (FDA) and are currently under development and validation.

Be the First to Know

Stay up to date with media features, clinical milestones, and where to find us next.

Email

PRODUCTS
- CANCER PRE-SCREENING
- BRCA GERMLINE
TECH & SCIENCE
CLINICAL TRIALS
- THE RAINBOW STUDY
- THE PINK STUDY
ABOUT
LET'S CONNECT
INVEST

bottom of page